Functional testing methods for the antiplatelet effects of aspirin

Area of Science:

• Pharmacology and Cardiovascular Medicine

Background:

• Aspirin irreversibly inhibits platelet cyclooxygenase-1 (COX-1) to block thromboxane A2 (TXA2) formation, crucial for its antiplatelet effect.
• Pharmacodynamic aspirin failure occurs in 1-2% of patients, with most atherothrombotic events linked to residual platelet reactivity.
• Existing platelet function assays lack specificity for aspirin's pharmacological effect and face standardization issues.

Purpose of the Study:

• To evaluate the utility and limitations of various assays in monitoring aspirin's antiplatelet efficacy.
• To assess the relationship between laboratory measurements and clinical outcomes in patients on aspirin therapy.

Main Methods:

• Review of direct measurement of thromboxane-forming capacity as the most specific assay for aspirin's pharmacological effect.
• Consideration of urinary 11-dehydro-thromboxane B2 as an in vivo index of TXA2 biosynthesis.
• Analysis of platelet-derived biomarkers like P-selectin and soluble CD40 ligand.

Main Results:

• No linear correlation exists between TXA2 formation inhibition and overall platelet function inhibition.
• Urinary 11-dehydro-thromboxane B2 levels are sensitive to other TXA2 sources beyond platelet inhibition.
• Global platelet activation tests can identify high residual reactivity but are not specific to aspirin's pharmacological action.

Conclusions:

• Monitoring aspirin treatment via platelet function tests or biomarkers is not recommended for clinical practice.
• A clear relationship between assay results and clinical outcomes must be established before routine monitoring is advised.
• Further research is needed to validate assays for predicting clinical outcomes in aspirin-treated patients.